| Primary Hospice Care, Inc 7127 Laurel Canyon Blvd., N Hollywood, CA, 91605 | |
| (818) 764-1710 |
News Archive
In patients with a suspected acute coronary syndrome (ACS; such as heart attack or unstable angina), use of a more sensitive test to detect the protein troponin in blood was associated with increased diagnosis of a heart attack and improved identification of patients at high risk of another heart attack and death in the following year, according to a study in the March 23/30 issue of JAMA.
BioMimetic Therapeutics, Inc. announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.
A living retina fragment on a chip, working as a model for the eye, will enable eye disease research, as well as the development of personalized treatment strategies.
PROLOR Biotech, Inc.,, a company developing next generation biobetter therapeutic proteins, today announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of PROLOR's common stock on the TASE beginning on Thursday, May 27, 2010. At that time, the company's common stock will be listed on both the NYSE Amex in the United States and the TASE in Israel.
› Verified 3 days ago
| Name | Primary Hospice Care, Inc |
|---|---|
| Location | 7127 Laurel Canyon Blvd., N Hollywood, California |
| Hospice ID | 551712 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| SSA county code | 200 |
News Archive
In patients with a suspected acute coronary syndrome (ACS; such as heart attack or unstable angina), use of a more sensitive test to detect the protein troponin in blood was associated with increased diagnosis of a heart attack and improved identification of patients at high risk of another heart attack and death in the following year, according to a study in the March 23/30 issue of JAMA.
BioMimetic Therapeutics, Inc. announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.
A living retina fragment on a chip, working as a model for the eye, will enable eye disease research, as well as the development of personalized treatment strategies.
PROLOR Biotech, Inc.,, a company developing next generation biobetter therapeutic proteins, today announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of PROLOR's common stock on the TASE beginning on Thursday, May 27, 2010. At that time, the company's common stock will be listed on both the NYSE Amex in the United States and the TASE in Israel.
› Verified 3 days ago
| NPI Number | 1538453188 |
| Organization Name | Primary Hospice Care Inc |
| Address | 7127 Laurel Canyon Blvd North Hollywood, California, 91605 |
| Phone Number | (818)764-1710 |
News Archive
In patients with a suspected acute coronary syndrome (ACS; such as heart attack or unstable angina), use of a more sensitive test to detect the protein troponin in blood was associated with increased diagnosis of a heart attack and improved identification of patients at high risk of another heart attack and death in the following year, according to a study in the March 23/30 issue of JAMA.
BioMimetic Therapeutics, Inc. announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.
A living retina fragment on a chip, working as a model for the eye, will enable eye disease research, as well as the development of personalized treatment strategies.
PROLOR Biotech, Inc.,, a company developing next generation biobetter therapeutic proteins, today announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of PROLOR's common stock on the TASE beginning on Thursday, May 27, 2010. At that time, the company's common stock will be listed on both the NYSE Amex in the United States and the TASE in Israel.
› Verified 3 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | Not Available | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | Not Available | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | Not Available | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | Not Available | 97.3 |
| Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
In patients with a suspected acute coronary syndrome (ACS; such as heart attack or unstable angina), use of a more sensitive test to detect the protein troponin in blood was associated with increased diagnosis of a heart attack and improved identification of patients at high risk of another heart attack and death in the following year, according to a study in the March 23/30 issue of JAMA.
BioMimetic Therapeutics, Inc. announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.
A living retina fragment on a chip, working as a model for the eye, will enable eye disease research, as well as the development of personalized treatment strategies.
PROLOR Biotech, Inc.,, a company developing next generation biobetter therapeutic proteins, today announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of PROLOR's common stock on the TASE beginning on Thursday, May 27, 2010. At that time, the company's common stock will be listed on both the NYSE Amex in the United States and the TASE in Israel.
› Verified 3 days ago
| Home Health Aides | 3 |
| Counselors | 1 |
| Licensed Practical or Vocational Nurses | 4 |
| Medical Social Workers | 1 |
| Physicians | 1 |
| Registered Nurses | 2 |
| Total Employees | 12 |
|---|
News Archive
In patients with a suspected acute coronary syndrome (ACS; such as heart attack or unstable angina), use of a more sensitive test to detect the protein troponin in blood was associated with increased diagnosis of a heart attack and improved identification of patients at high risk of another heart attack and death in the following year, according to a study in the March 23/30 issue of JAMA.
BioMimetic Therapeutics, Inc. announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.
A living retina fragment on a chip, working as a model for the eye, will enable eye disease research, as well as the development of personalized treatment strategies.
PROLOR Biotech, Inc.,, a company developing next generation biobetter therapeutic proteins, today announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of PROLOR's common stock on the TASE beginning on Thursday, May 27, 2010. At that time, the company's common stock will be listed on both the NYSE Amex in the United States and the TASE in Israel.
› Verified 3 days ago
| Others | 2 |
| Total Volunteers | 2 |
|---|
News Archive
In patients with a suspected acute coronary syndrome (ACS; such as heart attack or unstable angina), use of a more sensitive test to detect the protein troponin in blood was associated with increased diagnosis of a heart attack and improved identification of patients at high risk of another heart attack and death in the following year, according to a study in the March 23/30 issue of JAMA.
BioMimetic Therapeutics, Inc. announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.
A living retina fragment on a chip, working as a model for the eye, will enable eye disease research, as well as the development of personalized treatment strategies.
PROLOR Biotech, Inc.,, a company developing next generation biobetter therapeutic proteins, today announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of PROLOR's common stock on the TASE beginning on Thursday, May 27, 2010. At that time, the company's common stock will be listed on both the NYSE Amex in the United States and the TASE in Israel.
› Verified 3 days ago
| Golden Days Hospice Care, Inc. Location: 10545 Burbank Blvd. #124, N Hollywood, California, 91601 Phone: (818) 764-1710 |
| Kmd Hospice, Inc. Location: 11631 Victory Blvd, Ste 201, N Hollywood, California, 91606 Phone: (818) 764-1710 |
| California Hospice Care Location: 8001 Laurel Canyon Blvd, Ste 206, N Hollywood, California, 91605 Phone: (818) 764-1710 |
| Primary Hospice Care, Inc Location: 7127 Laurel Canyon Blvd., N Hollywood, California, 91605 Phone: (818) 764-1710 |